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2410Objective: This study compared differences in patient outcomes and operative parameters for extracorporeal
membrane oxygenation (ECMO) versus cardiopulmonary bypass (CPB) in patients undergoing lung transplants.
Methods: Between January 1, 2008, and July 13, 2013, 316 patients underwent lung transplants at our institu-
tion, 102 requiring intraoperative mechanical cardiopulmonary support (CPB, n ¼ 55; ECMO, n ¼ 47). We
evaluated survival, blood product transfusions, bleeding complications, graft dysfunction, and rejection.
Results: Intraoperatively, the CPB group required more cell saver volume (1123  701 vs 814  826 mL;
P ¼ .043), fresh-frozen plasma (3.64  5.0 vs 1.51  3.2 units; P ¼ .014), platelets (1.38  1.6 vs 0.43 
1.25 units; P¼ .001), and cryoprecipitate (4.89 6.3 vs 0.85 2.8 units; P<.001) than the ECMO group. Post-
operatively, the CPB group received more platelets (1.09  2.6 vs 0.13  0.39 units; P ¼ .013) and was more
likely to have bleeding (15 [27.3%] vs 3 [6.4%]; P ¼ .006) and reoperation (21 [38.2%] vs 7 [14.9%];
P ¼ .009]. The CPB group had higher rates of primary graft dysfunction at 24 and 72 hours (41 [74.5%] vs
23 [48.9%]; P ¼ .008; and 42 [76.4%] vs 26 [56.5%]; P ¼ .034; respectively). There were no differences in
30-day and 1-year survivals.
Conclusions: Relative to CPB, the ECMO group required fewer transfusions and had less bleeding, fewer
reoperations, and less primary graft dysfunction. There were no statistically significant survival differences at
30 days or 1 year. (J Thorac Cardiovasc Surg 2014;148:2410-6)Since the advent of lung transplantation, the use of partial or
full cardiopulmonary support has been a necessary compo-
nent of the operation.1 As the operative technique has
become more streamlined, ventilation strategies have
become more efficient, and hemodynamic support options
have improved, the use of extracorporeal cardiopulmonary
support is no longer ubiquitous in lung transplantation.
Program-specific preferences, in addition to patient charac-
teristics such as pulmonary hypertension, intolerance of
single-lung ventilation, and right ventricular failure, howev-
er, still necessitate the use of cardiopulmonary support.
The use of cardiopulmonary bypass (CPB) has been
shown to be a safe method of intraoperative management,2,3
but it remains controversial.4 CPB has been shown to be at
least partly responsible for the development of lung injury
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The Journal of Thoracic and Cardiovascular Surundergoing operations other than transplants.5 The data
on the causality of CPB in primary graft dysfunction
(PGD) and recipient outcomes after lung transplants are
varied and often confounded,6,7 but there is a theoretic
risk of CPB inciting a biochemical cascade that could
lead to a suboptimal early postoperative course.5,6 In
addition to the risk of PGD, the use of CPB requires
full systemic heparinization, which can lead to more
substantial bleeding and use of blood products.8
The use of extracorporeal membrane oxygenation
(ECMO) for intraoperative cardiopulmonary support has
gained traction in recent years. There is growing experience
with the preoperative use of ECMO as a bridge to a
transplant in patients with refractory respiratory failure.9-12
In addition, the use of ECMO in patients with severe PGD
and acute rejection after a transplant has been documented
with good results.13,14 Because of the potential pulmonary
complications of CPB and the widespread use of ECMO,
several lung transplant centers have begun to use
intraoperative ECMO instead of CPB, with mixed
results.15-17 ECMO has potential advantages in that there is
no venous reservoir or cardiotomy suction, leading to
lessened blood-air interface, and it also allows an easy
transition to postoperative ECMO for cardiopulmonary sup-
port if necessary. Beginning in 2011, our transplant center
began incorporating ECMO intraoperatively in lieu of CPB
when feasible. In this study, we compare the outcomes of pa-
tients who underwent lung transplant requiring cardiopulmo-
nary support between thosewithECMOwith thosewithCPB.gery c November 2014
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
ECMO ¼ extracorporeal membrane oxygenation
PGD ¼ primary graft dysfunction
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Patients
We retrospectively reviewed all lung transplants performed at our center
between January 1, 2008, and July 13, 2013. During this time, we per-
formed 316 lung transplants; of these, 102 (32.3%) required intraoperative
cardiopulmonary support. Of these 102 patients, 47 (46%) received ECMO
support (ECMO group) and 55 (54%) received CPB support (CPB group).
All but 2 transplants in the ECMO group were performed after March 4,
2011, whereas there were only 10 performed in the CPB group after that
date. Among the ECMO group, 22 patients (46.8%) had peripheral venoar-
terial support, 15 (31.9%) had central ECMO support, 6 (10.6%) had ve-
novenous support, and 3 (4.3%) had a combination of central and
peripheral cannulation. Among the CPB group, 52 patients (94.5%) had
central CPB support, 2 (3.6%) had a combination of central and peripheral
cannulation, and 1 (1.8%) had peripheral cannulation. The records of the
47 ECMO group patients and 55 CPB group patients were retrospectively
reviewed. The preoperative, intraoperative, and postoperative data were
compared between the 2 groups. Follow-up ended on September 20,
2013, and was 100% complete. This study was approved by the Columbia
University institutional review board and performed in accordance with
accepted ethical standards.
Operative Techniques
CPBwas instituted through cannulation of the ascending aorta and right
atrium in most cases. In 2 cases, we used an existing right internal jugular
venous ECMO cannula for drainagewith aortic cannulation, and in another
case we used the common femoral vein and artery for peripheral cannula-
tion. Before aortic cannulation, 300 IU/kg of intravenous heparin was
administered to target an activated clotting time greater than 400 seconds.
Protamine was given to antagonize heparin on weaning from CPB. The
CPB circuit consisted of a Rotaflow pump (MAQUET Cardiovascular,
LLC, Wayne, NJ), Sorin Synthesis oxygenator (Sorin Group, Milan, Italy),
and Sorin tubing pack.
ECMO has been used routinely during lung transplants at our institution
since 2011. The cannulation technique and types were variable. After a
heparin bolus of between 3000 and 5000 units, patients were cannulated
peripherally, centrally, or a combination.
When performing central or hybrid central and peripheral cannulation
for ECMO (n ¼ 19; 40.4%), we inserted a femoral venous drainage can-
nula and an aortic cannula for central support. We prefer this configuration
if the patient has a relatively preserved intrinsic cardiac output but a lung
function so poor that the carotid and coronary circulation is receiving inad-
equate oxygenated blood. In a femorofemoral venoarterial ECMO config-
uration, the retrograde arterial reinfusion does not provide adequate upper
body oxygenation for these patients. We then make the decision to cannu-
late a peripheral artery or aorta according to the absence or presence of a
persistently low PaO2 from the right radial arterial line.
When performing peripheral cannulation, we use the femoral artery and
vein except when the patient has an existing upper body ECMO configura-
tion that uses the right internal jugular vein and subclavian artery. We do
not routinely sew a beveled graft to the femoral artery except when we
anticipate the need for postoperative ECMO or in cases of small vessels
at risk for limb ischemia.
The ECMO system consisted of a Rotaflow (Maquet) centrifugal pump,
Quadrox i or D (Maquet) membrane oxygenator, and Cobe Pack (Sorin)
3/8-inch tubing system. Intravenous heparin was given at the onset ofThe Journal of Thoracic and Carcannulation and maintained with a low-dose intravenous infusion during
the case. No protamine was given on weaning. If ECMO was continued
postoperatively, patients were maintained on a low-dose heparin infusion
on arrival to the intensive care unit, with activated partial thromboplastin
time maintained between 40 and 60 seconds.
Statistical Analysis
Data are expressed as mean  SD or number with percentage. Survival
was plotted with Kaplan-Meier curves and compared by the log-rank test.
Means were compared with the 2-sample Student t test to determine statis-
tical significance between groups. Categoric data were analyzed by c2 tests
or, if expectations were too low, Fisher exact tests. Statistical analysis
was performed with the SPSS software package (version 21.0; IBM,
Armonk, NY).RESULTS
Preoperative Data
Between January 1, 2008, and July 13, 2013, a total of
316 patients underwent lung transplants. Among these,
102 patients (32.3%) required intraoperative cardiopulmo-
nary support. Of these 102 patients, 47 (46%) received
ECMO support and 55 (54%) received CPB support. Base-
line patient characteristics were similar between the 2
groups (Table 1).
The underlying pathology leading to the lung transplant
was not significantly different between the ECMO and
CPB groups. In addition, the degree of patient illness, as
measured by the 6-minute walk test, forced vital capacity
and forced expiratory volume in 1 second, lung allocation
score, and pretransplant pulmonary arterial systolic pres-
sures, was not different between the groups. The ECMO
group did have a higher percentage of pretransplant
ECMO (10 [21.3%] vs 4 [7.3%]; P ¼ .04; Table 1).Operative Data
In the CPB group, 48 patients (87.3%) a sequential bilat-
eral lung transplant and the remaining 7 (12.7%) received a
single-lung transplant. In the ECMO group, 35 patients
(72.9%) received a sequential bilateral lung transplant and
the remaining 12 (27.1%) received a single-lung transplant.
Themean ischemic times were similar between the 2 groups
with the first, second, and single-lung ischemic times being
269  81.1, 351  81.1, and 335  50.9 minutes, respec-
tively, in the CPB group, and 281  81.2, 376  81.2, and
315 68.9 minutes, respectively, in the ECMO group. Total
cardiopulmonary support time was not significantly
different between the CPB and ECMO groups (196  80.2
vs 209  73.6 minutes; P ¼ .387). There was a statistically
significant difference in cannulation location between
groups, with 52 patients in the CPB group (94.5%) cannu-
lated centrally and 29 patients in the ECMO group
(61.7%) cannulated peripherally (P<.001; Table 2).
The intraoperative use of blood products was different
between the 2 groups. The intraoperative transfusion of
packed red blood cell units trended higher in the CPB groupdiovascular Surgery c Volume 148, Number 5 2411
TABLE 1. Baseline characteristics
Variable CPB (n ¼ 55) ECMO (n ¼ 47) P value
Female 28 (50.9%) 22 (46.8%) .68
Age (y) 46.9  15.9 50.8  14.9 .208
Body mass index (kg/m2) 23.5  5.5 24.0  4.6 .65
Blood group .431
A 19 (34.5%) 12 (25%)
B 8 (14.5%) 12 (25%)
AB 2 (3.6%) 3 (6.3%)
O 26 (47.3%) 20 (41.7%)
6-min walk test (m) 287  156 260  135 .364
Forced vital capacity
(% predicted)
42.7  15.3 42.6  15.4 .97
FEV1 (% predicted) 36.6  16.9 35.8  18.6 .84
Cytomegalovirus risk .742
Low 11 (20%) 11 (22.9%)
Intermediate 24 (43.6%) 17 (35.4%)
High 20 (36.4%) 19 (39.6%)
Preoperative hospitalization 16 (29.1%) 16 (34.0%) .591
Preoperative ICU 11 (20%) 14 (29.8%) .252
Preoperative vasopressor
or inotrope
1 (1.8%) 1 (2.1%) >.999
Preoperative ECMO 4 (7.3%) 10 (21.3%) .04
Preoperative mechanical
ventilation
4 (7.3%) 6 (12.5%) .507
Underlying pathology .723
Cystic fibrosis 11 (20%) 12 (25.5%)
COPD 7 (12.7%) 3 (6.3%)
IPF or ILD 21 (38.2%) 19 (39.6%)
Primary pulmonary
hypertension
3 (5.5%) 1 (2.1%)
Retransplant 4 (7.3%) 2 (4.3%)
Other 9 (16.4%) 10 (21.3%)
LAS 61.9  20.0 62.0  22.8 .989
Pretransplant systolic
PAP (mm Hg)
54.8  23.4 47.3  22.1 .105
Data are represented as mean  SD or number with percentage. CPB, Cardiopulmo-
nary bypass; ECMO, extracorporeal membrane oxygenation; FEV1, forced expiratory
volume in 1 second; ICU, intensive care unit; COPD, chronic obstructive pulmonary
disease; IPF, idiopathic pulmonary fibrosis; ILD, interstitial lung disease; LAS, lung
allocation score; PAP, pulmonary arterial pressure.
TABLE 2. Intraoperative data
Variable CPB (n ¼ 55) ECMO (n ¼ 47) P value
Double lung transplant 48 (87.3%) 35 (72.9%) .098
Associated cardiac
procedure
5 (9.1%) 0 (0%) .06
First lung ischemic time
(min)
269  81.1 281  81.2 .477
Second lung ischemic time
(min)
351  81.1 376  81.2 .158
Single lung ischemic time
(min)
335  50.9 315  68.9 .521
Bypass time (min) 196  80.2 209  73.6 .387
Cannulation location <.001
Central 52 (94.5%) 16 (34%)
Peripheral 1 (1.8%) 29 (61.7%)
Combined 2 (3.6%) 3 (6.4%)
Cannulation configuration <.001
Venovenous 0 (0%) 6 (12.8%)
Venoarterial 1 (1.8%) 22 (46.8%)
Venovenoarterial 0 (0%) 1 (2.1%)
Vena cava/RA-aorta 52 (94.5%) 15 (31.9%)
Other 2 (3.6%) 3 (6.4%)
Intraoperative blood
products
PRBCs (units) 5.24  5.7 3.6  3.2 .081
Cell saver (mL) 1123  701 814  826 .043
FFP (units) 3.64  5.0 1.51  3.2 .014
Platelets (6-packs) 1.38  1.6 .43  1.25 .001
Cryoprecipitate (units) 4.89  6.3 .85  2.8 <.001
Estimated blood loss (mL) 604  723 634  1004 .862
Data are represented as mean  SD or number with percentage. CPB, Cardiopulmo-
nary bypass; ECMO, extracorporeal membrane oxygenation; RA, right atrium;
PRBCs, packed red blood cells; FFP, fresh-frozen plasma.
Cardiothoracic Transplantation and Mechanical Circulatory Support Biscotti et al
T
Xrelative to the ECMO group (5.24  5.7 vs 3.6  3.2 units;
P ¼.081). Intraoperative cell saver use was also higher in
the CPB group (1123  701 vs 814  826 mL;
P ¼ .043). More units of fresh-frozen plasma were trans-
fused in the CPB group during the operation as well (3.64
 5.0 vs 1.51  3.2; P ¼ .014). Platelet transfusion was
significantly higher in the CPB group relative to the
ECMO group (1.38  1.6 vs 0.43  1.25 6-packs;
P ¼ .001). In addition, cryoprecipitate was used more
frequently in the CPB group than in the ECMO group
(4.89  6.3 vs 0.85  2.8 units; P < .001). Although
the CPB group did require more intraoperative blood
products, the estimated blood loss was not significantly
different between the CPB and ECMO groups (604  723
vs 634  1004 mL; P ¼ .862; Table 2).2412 The Journal of Thoracic and Cardiovascular SurPostoperative Data
Postoperatively, 3 patients in the CPB group (5.5%) and
5 in the ECMO group (10.6%) required continued support
ECMO (P ¼ .465), and 4 patients in the CPB group
(7.3%) and 4 in the ECMO group (8.5%) required
reinstitution of ECMO during the intensive care unit
stay (P> .999). The difference in the use of blood prod-
ucts in the postoperative period was not as statistically sig-
nificant as during the intraoperative period, although the
CPB group still tended to require more transfusions.
Packed red blood cell unit transfusion trended higher in
the CPB group (4.75  11.9 vs 1.57  2.6 units;
P ¼ .077). The difference in fresh-frozen plasma unit
transfusion nearly reached statistical significance, with
the CPB group requiring 3.67  10.1 units versus 0.68
 2.4 units in the ECMO group (P ¼ .051). Postoperative
platelet transfusion, in fact, did reach statistical signifi-
cance, with the CPB group requiring 1.09  2.6 units
versus 0.13  .39 6-packs in the ECMO group (P ¼ .013).
Postoperative complications, including cerebrovascular
accident, initiation of renal replacement therapy, trach-
eostomy, vascular complications, and cardiopulmonarygery c November 2014
TABLE 3. Postoperative outcomes
Variable CPB (n ¼ 55) ECMO (n ¼ 47) P value
Postoperative ECMO 3 (5.5%) 5 (10.6%) .465
Secondary ECMO 4 (7.3%) 4 (8.5%) >.999
Postoperative blood products
PRBCs (units) 4.75  11.9 1.57  2.6 .077
FFP (units) 3.67  10.1 0.68  2.4 .051
Platelets (6-packs) 1.09  2.6 0.13  0.39 .013
Cryoprecipitate (units) 0.82  2.6 0.43  2.9 .478
Complications
CVA 2 (3.6%) 3 (6.4%) .66
Hemodialysis 8 (14.5%) 4 (8.5%) .346
Tracheostomy 18 (32.7%) 10 (21.3%) .196
Reoperation 21 (38.2%) 7 (14.9%) .009
Vascular complications 2 (3.6%) 3 (6.4%) .66
Bleeding 15 (27.3%) 3 (6.4%) .006
CPR or cardiac arrest 7 (12.7%) 3 (6.4%) .335
ICU stay (d) 13.0  13.1 10.4  8.4 .25
30-d survival 53 (96.4%) 44 (93.6%) .66
Rejection 15 (27.3%) 10 (21.3%) .483
Any PGD at 24 h 41 (74.5%) 23 (48.9%) .008
PGD grade at 24 h .067
Grade 0 14 (25.5%) 24 (51.1%)
Grade 1 16 (29.1%) 9 (19.1%)
Grade 2 8 (14.5%) 5 (10.6%)
Grade 3 17 (30.9%) 9 (19.1%)
Any PGD at 72 h 42 (76.4%) 26 (56.5%) .034
PGD grade at 72 h .188
Grade 0 13 (23.6%) 20 (43.5%)
Grade 1 21 (38.2%) 14 (30.4%)
Grade 2 7 (12.7%) 5 (10.9%)
Grade 3 14 (25.5%) 7 (15.2%)
FEV1 (% predicted) 57.0  19.3 52.5  15.2 .22
Data are represented as mean  SD or number with percentage. CPB, Cardiopulmo-
nary bypass; ECMO, extracorporeal membrane oxygenation; PRBCs, packed red
blood cells; FFP, fresh-frozen plasma; CVA, cerebrovascular accident; CPR, cardio-
pulmonary resuscitation; ICU, intensive care unit; PGD, primary graft dysfunction;
FEV1, forced expiratory volume in 1 second.
FIGURE 1. Kaplan-Meier survival curve out to 1 year. CPB, Cardiopul-
monary bypass; ECMO, extracorporeal membrane oxygenation.
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groups. More patients in the CPB group than in the
ECMO group had significant postoperative bleeding,
defined as reoperation for bleeding or transfusion of
more than 6 units of packed red blood cells (15
[27.3%] vs 3 [6.4%]; P ¼ .006). In addition, there
were more reoperations in the postoperative period in
the CPB group than in the ECMO group (21 [38.2%]
vs 7 [14.9%]; P ¼ .009).
According to the International Society for Heart and
Lung Transplantation lung transplant injury grades for
PGD, the CPB group was more likely to have any PGD at
both 24 and 72 hours than was the ECMO group (41
[74.5%] vs 23 [48.9%]; P ¼ .008; and 42 [76.4%] vs 26
[56.5%]; P ¼ .034; respectively; Table 3). There were no
statistically significant differences in 30-day and 1-year sur-
vivals between the CPB group and the ECMO group
(Figure 1).The Journal of Thoracic and CarDISCUSSION
In current practice, most lung transplants are not per-
formed with intraoperative cardiopulmonary support. At
our institution, we have performed 316 transplants in the
last 5 years, and only 102 (32.3%) required intraoperative
extracorporeal mechanical support. There are many
situations in which the use of either CPB or ECMO is un-
avoidable, however, and these include inability to tolerate
single-lung ventilation, right ventricular failure, and pulmo-
nary hypertension. Historically, CPB was the mechanical
support system of choice because it had proved successful
in cardiac surgery for decades and more recently in lung
transplantation as well.2,3 The use of an extracorporeal
mechanical support system, however, is not without risk.
There is concern that the CPB system can incite an
inflammatory response that damages end organs and
should be avoided in lung transplantation.4 There is addi-
tional data that CPB can lead to acute lung injury and acute
respiratory distress syndrome in patients undergoing opera-
tions other than transplants, which would make its utility for
lung transplants even more questionable.5 Further data,
including those from the International Society for Heart
and Lung Transplantation working group on lung PGD,
have suggested that CPB can be directly linked to worse
postoperative outcomes and higher rates of PGD.6-8
To avoid the potential complications of CPB, many
groups have begun replacing CPB with intraoperative
ECMO when mechanical circulatory support is required.
Preliminary data regarding the utility of ECMO relative to
CPB is varied. A study by Bittner and colleagues16 in
2006 suggested that ECMO use led to higher rates of blood
product transfusions, as well as worse 1-year survivals.16 A
more recent report from Ius and coworkers15 in 2012
demonstrated lower blood product transfusion rates and
improved survivals at 3, 9, and 12 months in the ECMO
group relative to the CPB group.15diovascular Surgery c Volume 148, Number 5 2413
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operative CPB to ECMO, we sought to compare intraoper-
ative and postoperative outcomes between the 2 groups.
Although we did not demonstrate a statistically significant
1-year survival difference between the 2 groups, there
were several clinically meaningful outcomes in favor of
the ECMO group. Patients who received intraoperative
ECMO required fewer intraoperative and postoperative
blood product transfusions. In addition, the ECMO group
had fewer instances of postoperative bleeding and required
fewer posttransplant reoperations. Patients who received in-
traoperative CPB were also more likely to have any PGD at
both 24 and 72 hours than were those in the ECMO group.
We believe that the lower PGD rates in the ECMO group
can be explained both by the fewer blood product transfu-
sions and by the relative blood biocompatibility advantage
of the ECMO circuit. The ECMO circuit is simpler than
the CPB circuit, has less blood-tubing interface surface
area, has less blood-air interface, and lacks a cardiotomy
reservoir, all of which lead to a theoretic decrease in activa-
tion of a systemic inflammatory response.
Study Limitations
This study was a single-center, retrospective review. The
results also may be confounded by the fact that the trans-
plants performed with CPB were performed mostly in the
first 3 years of the study, whereas the transplants performed
with ECMO were performed in the final 2.5 years of the
study. This should not have significantly affected outcomes,
however, because the same 3 surgeons performed all 102
transplants with the same operative techniques during the
short 5-year course of the study. The follow-up for the
ECMO group, although complete, did not extend to 1
year for 15 patients (31.9%), potentially influencing 1-
year survival results. When reviewing all patients at our
center, however, there was no statistically significant differ-
ence between observed and expected 1-year survivals be-
tween the first half of the study and the second half of the
study. From January 1, 2008, through June 30, 2010, the
1-year survival was 89.4% (based on 118 transplants),
with an observed to expected P value of .624. From July
1, 2010 through December 31, 2012, the 1-year survival
was 91.4% (based on 144 transplants), with an observed
to expected P value of .240.18,19 Because this comparison
was made among all transplant patients, whether they
required cardiopulmonary support or not, it suggests that
any difference in improved outcome was not related to an
improvement in overall survival between the 2 periods.
CONCLUSIONS
Intraoperative use of ECMO for lung transplants was
associated with lower transfusion requirements and use of
cell saver relative to CPB. Postoperatively, the ECMO
group had less bleeding, underwent fewer reoperations,2414 The Journal of Thoracic and Cardiovascular Surreceived less fresh-frozen plasma, and had less PGD. In
addition, ECMO confers the benefit of easy conversion to
posttransplant extracorporeal cardiopulmonary support if
required. There were, however, no statistically significant
survival differences between the 2 groups at 30 days and
1 year. ECMO has become our institution’s preferred
method for intraoperative cardiopulmonary support when
required during lung transplantation.References
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XDiscussion
Dr Michael J. Weyant (Aurora, Colo). Dr Biscotti, I enjoyed
reading the article that you sent me well in advance. You and
your coauthors are to be congratulated for exploring these novel
ways of supporting our patients through lung transplants, because
we all know the incidence of needing to support these patients will
probably go up as we continue to do lung transplants.
You suggest from your study that ECMO may be a more bene-
ficial method of supporting these patients through lung transplant,
and you suggest the reasons for that are your decreased blood
transfusions, the circuit being simpler, and the mechanical injury
of the blood cells being less.
I have a few questions, but I thought this study overall was quite
novel, and I plan to adopt some of these practices in my own work
with lung transplants. The first is that in looking at the patients who
had ECMO support in the operating room, were there any conver-
sions from ECMO to standard CPB? If there were, what were the
reasons for that?
Dr Biscotti. There were several instances in which we had to
convert to CPB, and thesewere mostly because of difficulty in con-
trolling bleeding where we needed cardiotomy suction. We didn’t
want to use several rounds of the cell saver, which tends to deplete
factors and can create its own set of problems. We generally
convert to CPB from ECMO when we encounter extensive
bleeding.
Dr Weyant. It’s not ‘‘several,’’ it’s a small number, which I
actually don’t think you emphasized enough, because the vast ma-
jority of patients who went to the operating room didn’t have their
strategy changed. And so to a critic of the use of ECMO, for
example, for this purpose, that would be your defense. And I think
when you submit the final article, maybe emphasizing that will be
more important.
And the other thing is that about a third of the patients in the
ECMO group you are talking about have what you describe as cen-
tral ECMO cannulation. Now, we all know what central cannula-
tion might be, but can you elaborate more on the actual
cannulation strategy for central ECMO versus peripheral
ECMO? I’m assuming the difference is most likely the placement
of the arterial cannula, but how do you decide where to put it?
Dr Biscotti. We don’t typically do it in the same way as the
CPB. We often use a femoral venous drainage cannula and then
insert an aortic cannula for central support, which can be done
through either a clamshell or thoracotomy, which are our preferred
surgical approaches to the chest. This is because if the patient has a
good intrinsic cardiac output but poor lung function, the carotid
and coronary circulation will have inadequate oxygenated blood
because retrograde venoarterial ECMO does not provide good up-
per body perfusion. In those cases that where we have to convert
from our typical groin arterial cannulation to our central aortic
cannulation, we can maintain the same peripheral drainage. If
we have any doubts or notice a severe and persistent drop in
PaO2 from the right radial artery, we will use or convert to a central
ECMO cannulation strategy.The Journal of Thoracic and CarDrWeyant. For my final question, you mentioned your antico-
agulation strategy for both your standard CPB and ECMO. For
those who are going to institute ECMO more as a way of support-
ing their patients, you seem to run it a little looser, without moni-
toring of activated clotting time and so on. What would you
suggest for programs that would initiate more ECMO support
versus CPB support and the use of activated clotting times and
more firm monitoring of the anticoagulation process?
I thought your talk was great and really enjoyed reading your
article.
Dr Biscotti. Thank you; I appreciate that. Our intraoperative
anticoagulation approach was greatly influenced by our experi-
ence with our intensive care unit–managed ECMO patients. We
did manage them with activated clotting time during the infancy
of the ECMO program; however, after demonstrating that there
really was no difference in system failure or cannula issues
such as clotting, whether the activated clotting time was measured
or we just followed partial thromboplastin times every 6, 12, or 24
hours, we then transitioned to not using activated clotting times,
and that is our current intraoperative protocol. Our perfusionists
will check an activated clotting time after the initial heparin bolus
to confirm that it has increased from baseline, but that is the last
clinical use of activated clotting time during the operation. Also,
because the ECMO technology, specifically biocompatibility, has
improved so much in the last 5 to 10 years, I think that low anti-
coagulation levels are probably reasonable for a 3- to 6-hour
ECMO run.
DrDaniel L.Miller (Marietta, Ga). I had done lung transplants
for 20 years and stopped December 31st when I went to my new
position, and I can’t believe I am asking a lung transplant question.
But my question is, I saw about a third of your circulatory support
was for an indication of interstitial lung disease and a very small
percentage was for primary pulmonary hypertension. Do you
have any insight into the patients who had interstitial lung disease?
What was the degree of pulmonary artery hypertension, and did
that correlate with your outcomes or need for CPB versus ECMO?
Dr Biscotti. Thank you for the question. I know between the
2 groups, at the very least, there was no difference in pulmonary
arterial pressures; however, I think that this is something that could
be looked at as far as the comparison of our pulmonary artery pres-
sures in these patients versus the ones who don’t require mechan-
ical circulatory support. I think generally one of the reasons we
make the decision preoperatively that we are going to use bypass
or ECMO is because, as you know, the pulmonary arterial pres-
sures are very high, but I don’t have a subgroup analysis of just
the patients with interstitial lung disease per se.
Dr Miller. From your experience, if you have elevated pulmo-
nary arterial pressures, which would you prefer?
Dr Biscotti. It seems that ECMO does a pretty good job in our
hands.
Dr Si Mai Pham (Baltimore, Md). I have 2 questions. First, in
which patients would you recommend using ECMO versus CPB if
you need to use cardiopulmonary support during a lung transplant
operation? Second, there was a study from Germany several years
ago from Friedrich Mohr’s group in which they compared ECMO
versus CPB in lung transplant operation, and they abandoned the
use of ECMO because the ECMO group had more bleeding and
more complications. So I wonder whether you are familiar with
that work, and what are differences between your work and theirs?diovascular Surgery c Volume 148, Number 5 2415
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XDr Biscotti. Thank you for your questions. To answer your sec-
ond question first, I am not sure whether it’s the same as that 2007
study that you were talking about, but I think it could be that they
ran their anticoagulation higher; additionally some of the circuitry
is different from what we use now. Perhaps the technology wasn’t
quite there in 2007, or maybe they were using a more complex cir-
cuit than ours, which is relatively simple and less thrombogenic.
Also, they studied their lung transplant program in its infancy;
from what I understand, they had just started their program. So
it is not necessarily comparable.
And I think for your first question, why we use ECMO versus
CPB or CPB versus ECMO, I know that if we anticipate a lot of
bleeding or if will have to do some intracardiac procedure, such
as closing an atrial septal defect, then we would definitely use
CPB. But at this point in our institution, we use ECMO unless
one of those situations arises.
Dr Michael S. Mulligan (Seattle, Wash). What was your inci-
dence of limb complications in your groin access group?
Dr Biscotti. I don’t remember the exact number. I know that
there was no difference between the groups. We generally don’t
use distal perfusion cannulas if we don’t have to, only if we antic-
ipate that we will have to continue support postoperatively.
DrMulligan.What was your incidence of insufficient drainage
with groin cannulation? This is a common problem that surgeons
will talk about, and in fact it came up in the transplant symposium
yesterday that people were concerned about this. Are you seeing
this as a problem?
Dr Biscotti. I can’t answer that. I don’t know the answer to that,
but I think it is a reasonable question.
Dr Matthew Bacchetta (New York, NY). We actually have not
had to insert extra drainage cannulas. We choose cannulas
based on the expected need of the patient, which is a function of
their remaining native lung function and calculated cardiac output.
If we are doing a double-lung transplant, we approach them
sequentially and transplant the worst lung first (based on2416 The Journal of Thoracic and Cardiovascular Surventilation/perfusion scan data). This approach generally allows
us to flow at partial support levels even for patients with severe
pulmonary hypertension. We have found that 60% to 75% of
their calculated flow is more than adequate to support them
physiologically.
Regarding limb ischemia, we have not had a problem with
compromised limbs because we carefully size the femoral vessels
preoperatively with an ultrasound. If the required arterial cannula
looks close to causing limb ischemia, we cut down onto the artery
and sew a graft on it. Then, we cannulate the tunneled graft. This
approach eliminates the risk for limb ischemia.
Dr Mulligan. I may have misheard, but it sounds like you had
situations where you may have had groin venous cannulation and
central aortic cannulation, and if you are already in the chest and
you are going to centrally cannulate for a return, paint me a sce-
nario in which you wound up having sort of one purpose for
each access.
Dr Bacchetta. If the patient’s native lung function is extremely
poor and she might not tolerate partial flow with sequential trans-
plant, or if she develops severe hemodynamic instability while I
have the chest open, I can cannulate the aorta while my resident
cannulates the femoral vein. It saves a small amount of time, but
mostly it keeps the venous cannula out of the right atrium, which
can be mildly nettlesome when clamping the pulmonary veins/left
atrium.
Dr Mulligan. So this is not a planned strategy in which you
have something in the groin and something in the chest?
Dr Bacchetta. Sometimes it is part of the plan since I prefer
to keep venous cannulas out of the right atrium. I don’t like
having a dual-stage venous cannula in the atrium because, as
I mentioned earlier, it can make clamping the pulmonary
veins/left atrium more cumbersome. I usually insert the femoral
venous cannula up to the atrial-inferior vena cava junction,
which allows for good drainage while keeping it out of the right
atrium.gery c November 2014
